p21(WAF1) regulates anchorage-independent growth of HCT116 colon carcinoma cells via E-cadherin expression

Cancer Research

Volumn 60, Issue 1, 2000, Pages 156-163

  Mueller, Sebastian ^a,b   Cadenas, Enrique ^b   Schönthal, Axel H ^c,d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d Dept Molec Microbiol and Immunol ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P21; PROTEIN P53; UVOMORULIN; ANTIBODY; ANTINEOPLASTIC ANTIBIOTIC; ANTISENSE OLIGONUCLEOTIDE; CADHERIN; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; DAUNORUBICIN; TUMOR PROTEIN;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CARCINOMA CELL; CELL ADHESION; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CHEMOSENSITIVITY; CHICK EMBRYO; COLON CARCINOMA; GROWTH REGULATION; HUMAN; HUMAN CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN INDUCTION; ANIMAL; APOPTOSIS; CELL COMMUNICATION; CELL CULTURE; CELL DIVISION; COLON TUMOR; DRUG EFFECT; GENETIC TRANSFECTION; GENETICS; METABOLISM; NICK END LABELING; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES; APOPTOSIS; CADHERINS; CELL ADHESION; CELL COMMUNICATION; CELL DIVISION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CHICK EMBRYO; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DAUNORUBICIN; HUMANS; IN SITU NICK-END LABELING; NEOPLASM PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; PHENOTYPE; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0033621582     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. El-Deiry, W. S. p21/p53, cellular growth control and genomic integrity. Curr. Topics Microbiol. Immunol., 227: 121-137, 1998.
2. Harper, J. W., and Elledge, S. J. Cdk inhibitors in development and cancer. Curr. Opin. Genet. Dev., 6: 56-64, 1996.
3. 1 cyclin-dependent kinases. Genes Dev., 9: 1149-1163, 1995.
4. Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., and Vogelstein, B. A model for p53-induced apoptosis. Nature (Lond.), 389: 300-305, 1997.
5. Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., and Vogelstein, B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science (Washington DC), 282: 1497-1501, 1998.
6. Harris, C. C. p53 tumor suppressor gene: from the basic research laboratory to the clinic-an abridged historical perspective. Carcinogenesis (Lond.), 17: 1187-1198, 1996.
7. Waldman, T., Zhang, Y., Dillehay, L., Yu, J., Kinzler, K., Vogelstein, B., and Williams, J. Cell-cycle arrest versus cell death in cancer therapy. Nat. Med., 3: 1034-1036, 1997.
8. Waga, S., Hannon, G. J., Beach, D., and Stillman, B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature (Lond.), 369: 574-578, 1994.
9. Morgan, D. O. Principles of CDK regulation. Nature (Lond.), 374: 131-134, 1997.
10. Graña, X., and Reddy, E. P. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene, 11: 211-219, 1995.
11. Deng, C., Zhang, P., Harper, J. W., Elledge, S. J., and Leder, P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell, 82: 675-684, 1995.
12. Brugarolas, J., Chandraskeian, C., Gordon, I., Beach, D., Jacks, T., and Hannon, G. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature (Lond.), 377: 552-556, 1995.
13. Waldman, T., Lengauer, C., Kinzler, K. W., and Vogelstein, B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature (Lond.), 381: 713-716, 1996.
14. Fan, S., Chang, J. K., Smith, M. L., Duba, D., Fornace, A. J., Jr., and O'Connor, P. M. Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard. Oncogene, 14: 2127-2136, 1997.
15. Li, W. W., Fan, J., Hochhauser, D., and Bertino, J. R. Overexpression of p21waf1 leads to increased inhibition of E2F-1 phosphorylation and sensitivity to anticancer drugs in retinoblastoma-negative human sarcoma cells. Cancer Res., 57: 2193-2199, 1997.
16. McDonald, E. R., III, Wu, G. S., Waldman, T., and El-Deiry, W. S. Repair defect in p21 WAF1/C1P1-/-human cancer cells. Cancer Res., 56: 2250-2255, 1996.
17. Kamb, A. Cyclin-dependent kinase inhibitors and human cancer. Curr. Top. Microbiol. Immunol., 227: 139-148, 1998.
18. Shiohara, M., el-Deiry, W. S., Wada, M., Nakamaki, T., Takeuchi, S., Yang, R., Chen, D. L., Vogelstein, B., and Koeffler, H. P. Absence of WAF1 mutations in a variety of human malignancies. Blood, 84: 3781-3784, 1994.
19. Sutherland, R. M. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science (Washington DC), 240: 177-184, 1988.
20. Shin, S-I., Freedman, V. H., Risser, R., and Pollack, R. Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchorage independent growth in vitro. Proc. Natl. Acad. Sci. USA, 72: 4435-4439, 1975.
21. Freedman, V. H., and Shin, S. I. Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell, 3: 355-359, 1974.
22. Kawada, M., Uehara, Y., Mizuno, S., Yamori, T., and Tsuruo, T. Up-regulation of p27Kip1 correlates inversely with anchorage-independent growth of human cancer cell lines. Jpn. J. Cancer Res., 89: 110-115, 1998.
23. Kantak, S. S., and Kramer, R. H. E-Cadherin regulates anchorage-independent growth and survival in oral squamous cell carcinoma cells. J. Biol. Chem., 273: 16953-16961, 1998.
24. St. Croix, B., Sheehan, C., Rak, J. W., Florenes, V. A., Slingerland, J. M., and Kerbel, R. S. E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1). J. Cell Biol., 142: 557-571, 1998.
25. Geiger, B., and Ayalon, O. Cadherins. Annu. Rev. Cell Biol., 8. 307-332, 1992.
26. Takeichi, M. Morphogenetic roles of classic cadherins. Curr. Opin. Cell Biol., 7: 619-627, 1995.
27. Perl, A. K., Wilgenbus, P., Dahl, U., Semb, H., and Christofori. G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature (Lond.), 392: 190-193, 1998.
28. Bracke, M. E., Van Roy, F. M., and Mareel, M. M. The E-cadherin/calenin complex in invasion and metastasis. Curr. Top. Microbiol. Immunol., 213: 123-161, 1996.
29. Jankowski, J. A., Bruton, R., Shepherd, N., and Sanders, D. S. Cadherin and catenin biology represent a global mechanism for epithelial cancer progression. Mol. Pathol., 50: 289-290, 1997.
30. Yap, A. S. The morphogenetic role of cadherin cell adhesion molecules in human cancer: a thematic review. Cancer Investig., 16: 252-261, 1998.
31. LaRue, K. E., Bradbury, E. M., and Freyer, J. P. Differential regulation of cyclin-dependent kinase inhibitors in monolayer and spheroid cultures of tumorigenic and nontumorigenic fibroblasts. Cancer Res., 58: 1305-1314, 1998.
32. Fang, F., Orend, G., Watanabe, N., Hunter, T., and Ruoslahti, E. Dependence of cyclin E-CDK2 kinase activity on cell anchorage. Science (Washington DC), 271: 499-502, 1996.
33. Orend, G., Hunter, T., and Ruoslahti, E. Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells Oncogene, 16: 2575-2583, 1998.
34. Kawada, M., Yamagoe, S., Murakami, Y., Suzuki, K., Mizuno, S., and Uehara, Y. Induction of p27Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway. Oncogene, 15: 629-637, 1997.
35. waf1 pathway in response to disruption of cell-matrix interactions. J. Biol. Chem., 272: 29091-29098, 1997.
36. Zhu, X., Ohtsubo, M., Bohmer, R. M., Roberts, J. M., and Assoian, R. K. Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein. J. Cell Biol., 133: 391-403, 1996.
37. Waldman, T., Kinzier, K. W., and Vogelstein, B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res., 55: 5187-5190, 1995.
38. Zimmer, D. B., Cornwall, E. H., Reynolds, P. D., and Donald, C. M. S100A1 regulates neurite organization, tubulin levels, and proliferation in PC12 cells. J. Biol. Chem., 273: 4705-4711, 1998.
39. Rimm, D. L., Kebriaei, P., and Morrow, J. S. Molecular cloning reveals alternative splice forms of human alpha(E)-catenin. Biochem. Biophys. Res. Commun., 203: 1691-1699, 1994.
40. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
41. Poluha, W., Poluha, D. K., Chang, B., Crosbie, N. E., Schonhoff, C. M., Kilpatrick, D. L., and Ross, A. H. The cyclin-dependent kinase inhibitor p21 (WAF1) is required for survival of differentiating neuroblastoma cells. Mol. Cell. Biol., 16: 1335-1341, 1996.
42. Lewis, J. G., Lin, K. Y., Kothavale, A., Flanagan, W. M., Matteucci, M. D., DePrince, R. B., Mook, R. A., Jr., Hendren, R. W., and Wagner, R. W. A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. Proc. Natl. Acad Sci. USA, 93: 3176-3181, 1996.
43. Gavrieli, Y., Sherman, Y., and Ben-Sasson, S. A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol., 119: 493-501, 1992.
44. Koopman, G., Reutelingsperger, C. P., Kuijten, G. A., Keetmen, R. M., Pals, S. T., and van Oers, M. H. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood, 84: 1415-1420, 1994.
45. Kim, J., Yu, W., Kovalski, K., and Ossowski, L. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell, 94: 353-362, 1998.
46. Chakrabarty, S. Regulation of human colon-carcinoma cell adhesion to extracellular matrix by transforming growth factor β1. Int. J. Cancer, 50: 968-973, 1992.
47. St. Croix, B. S., Rak, J. W., Kapitain, S., Sheehan, C., Graham, C. H., and Kerbel, R. S. Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. J. Natl. Cancer Inst., 88: 1285-1296, 1996.
48. St. Croix, B., and Kerbel, R. S. Cell adhesion and drug resistance in cancer. Curr. Opin. Oncol., 9: 549-556, 1997.
49. Qiu, X., Schönthal, A. H., and Cadenas, E. Anticancer quinones induce retinoblastoma-inhibitable G2 arrest and apoptosis. Free Radical Biol. Med., 24: 848-854, 1998.
50. Chen, J., Willingham, T., Shuford, M., Bruce, D., Rushing, E., Smith, Y., and Nisen, P. D. Effects of ectopic overexpression of p21(WAF1/CIP1) on aneuploidy and the malignant phenotype of human brain tumor cells. Oncogene, 13: 1395-1403, 1996.
51. Eastham, J. A., Hall, S. J., Sehgal, I., Wang, J., Timme, T. L., Yang, G., Connell-Crowley, L., Elledge, S. I., Zhang, W. W., Harper, J. W., et al. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res., 55: 5151-5155, 1995.
52. Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Jr., Butel, J. S., and Bradley. A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (Lond.), 356: 215-221, 1992.
53. Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., and Weinberg, R. A. Tumor spectrum analysis in p53-mutant mice. Curr. Biol., 4: 1-7, 1994.
54. Weinberg, W. C., Fernandez-Salas, E., Morgan, D. L., Shalizi, A., Mirosh, E., Stanulis, E., Deng, C., Hennings, H., and Yuspa, S. H. Genetic deletion of p21WAF1 enhances papilloma formation but not malignant conversion in experimental mouse skin carcinogenesis. Cancer Res., 59: 2050-2054, 1999.
55. Greenhalgh, D. A., Wang, X. J., Donehower, L. A., and Roop, D. R. Paradoxical tumor inhibitory effect of p53 loss in transgenic mice expressing epidermal-targeted v-rasHa, v-fos, or human transforming growth factor α. Cancer Res., 56: 4413-4423, 1996.
56. Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Jr., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science (Washington DC), 250: 1233-1238, 1990.
57. Zhang, Y., Fujita, N., and Tsuruo, T. Caspase-mediated cleavage of p21Waf1/Cip1 converts cancer cells from growth arrest to undergoing apoptosis. Oncogene, 18: 1131-1138, 1999.
58. Suzuki, A., Tsutomi, Y., Miura, M., and Akahane, K. Caspase 3 inactivation to suppress Fas-mediated apoptosis: identification of binding domain with p21 and ILP and inactivation machinery by p21. Oncogene, 18: 1239-1244, 1999.
59. Wang, J., and Walsh, K. Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. Science (Washington DC), 273: 359-361, 1996.
60. Gorospe, M., Wang, X., Guyton, K. Z., and Holbrook, N. J. Protective role of p21(Waf1/Cip1) against prostaglandin A2-mediated apoptosis of human colorectal carcinoma cells. Mol. Cell. Biol., 16: 6654-6660, 1996.
61. Gorospe, M., Cirielli, C., Wang, X., Seth, P., Capogrossi, M. C., and Holbrook, N. J. p21(Waf1/Cip1) protects against p53-mediated apoptosis of human melanoma cells. Oncogene, 14: 929-935, 1997.
62. Dimanche-Boitrel, M. T., Genne, P., Duchamp, O., and Chauffert, B. Confluence dependent resistance (CDR) to doxorubicin and E-cadherin expression in murine mammary cells. Cancer Lett., 85: 171-176, 1994.
63. St. Croix, B., Florenes, V. A., Rak, J. W., Flanagan, M., Bhattacharya, N., Slingerland, J. M., and Kerbel, R. S. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat. Med., 2: 1204-1210, 1996.